Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, there have been
a few variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of …

The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly
due to altered antibody evasion properties deriving from their additional spike mutations …

A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant, BA.
2.86, has emerged and spread to numerous countries worldwide, raising alarm because its …

Continuous evolution of Omicron has led to a rapid and simultaneous emergence of
numerous variants that display growth advantages over BA. 5 (ref.). Despite their divergent …

The continued evolution of SARS-CoV-2 has led to the emergence of several new Omicron
subvariants, including BQ. 1, BQ. 1.1, BA. 4.6, BF. 7, and BA. 2.75. 2. Here, we examine the …

Abstract SARS-CoV-2 Omicron subvariants BA. 2.12. 1 and BA. 4/5 have surged notably to
become dominant in the United States and South Africa, respectively,. These new …

The Omicron, or Pango lineage B. 1.1. 529, variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages BA.
2.12. 1, BA. 4 and BA. 5 exhibit higher transmissibility than the BA. 2 lineage 1. The receptor …

Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …